AMGN · News · 20260804N
Market Demand Trends
AMGEN INC · 2026-08-04 · Importance 53 · Surprise 48
Amgen reported broad demand momentum across its commercial portfolio, with 22 products delivering double-digit sales growth in the second quarter. The six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Repatha generated $953 million in revenue, while Tezspire sales rose 42.1% year over year to $486 million, supported by demand in asthma and chronic rhinosinusitis with nasal polyps. Evenity, Uplizna, and Imdelltra also contributed to growth, offsetting weakness in older franchises.